logo
Share SHARE
FONT-SIZE Plus   Neg

Super Micro Computer Q3 Profit Slips - Quick Facts

Server solutions provider Super Micro Computer Inc. (SMCI), Tuesday reported a decline in profit, due mainly to higher operating expenses.

The San Jose, California-based company reported a third-quarter net profit of $7.08 million or $0.16 per share, compared to $10.70 million or $0.25 per share last year.

Excluding stock-based compensation expense, adjusted net income for the quarter declined to $8.81 million or $0.19 per share from $12.26 million from $0.28 per share in the prior-year quarter. On average, five analysts polled by Thomson Reuters expected the company to earn $0.23 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter grew 2.5 percent to $240.18 million from $234.29 million in the prior-year quarter. Five analysts had a consensus revenue estimate of $251.74 million for the quarter.

Operating expenses for the quarter increased to $31.14 million from $22.70 million in the prior-year quarter.

Looking ahead, the company expects fourth quarter adjusted earnings in the range of $0.27 to $0.32 per share. Revenues for the fourth quarter are anticipated in the range of $280 million to $310 million. Analysts currently expect the company to earn $0.29 per share for the quarter, with revenues of $274.88 million.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Database startup MongoDB has filed confidentially for initial public offering, aiming to go public before the end of the year, according to TechCrunch. The company, which develops enterprise-grade, open-source software including MongoDB NoSQL database, reportedly has submitted an S-1 filing in the past few weeks. Wal-Mart Stores Inc., the world's largest retailer, reported a decline in second-quarter profit with a significant charge. Adjusted earnings topped analysts' estimates with higher comparable sales. Looking ahead, for the third quarter, the company projects earnings in line or below market view. The company also issued earnings forecast for fiscal 2018. The development of Alzheimer's drugs has been marred by a high failure rate. A U.S. study, which analyzed how the Alzheimer's clinical trials fared during the period of 2002 to 2012, revealed a failure rate of 99.6% compared to a failure rate of 81% for cancer drugs.
comments powered by Disqus
Follow RTT